I think the conclusion will continue to elude us until the...

I think the conclusion will continue to elude us until the assays arrive.

Here's my logic (from a business valuation angle only):

I think the market is backing Chris Cairns to a large extent on past performance (IMO) which leads me to believe that the magic number of 426million for the sale of integra is influencing buying decisions.

2 very different operations but I still think it's being used as a benchmark on market.

I think there's potential here for an asset that could dwarf integra in the long term.

But Integra at the time of sale was a fully fledged profitable gold producer and the price of 426m was considered a premium.

Svy is an unknown explorer with a pretty uncertain future at this stage, yet it's mcap has reached almost $250m at peak last Friday. Almost 60% of the Integra sale price.

I think the results of the coming assays will be great but to justify the sp and keep it moving upwards, they need to be something spectacular.

We have a roller coaster ahead of us.

P.S anyone about to reply with a half arsed shot at me for comparing Staveley to integra should reread this post in its entirety.